AstraZeneca’s MedImmune wins FDA complete response letter for motavizumab
The complete response letter is in connection with the biologics license application for motavizumab for the prevention of serious respiratory syncytial virus disease, which was submitted in January
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.